Vendors — bioprocess & CMC software / AI landscape厂商 — 生物工艺与 CMC 软件 / AI 格局
Most of this summit's ≈60 sponsors are equipment, resin, instrument, and CDMO suppliers. This page focuses on the competitively-relevant digital / AI / document cluster — and shows that only AuroraPrime and Weave Bio actually author CMC regulatory documents.
本峰会约 60 家赞助商绝大多数是设备、树脂、仪器与 CDMO 供应商。本页聚焦真正相关的数字 / AI / 文档集群——并揭示：真正撰写 CMC 监管文档的只有 AuroraPrime 与 Weave Bio。
Digital / AI vendors mapped
纳入的数字 / AI 厂商
incl. AuroraPrime benchmark
含 AuroraPrime 基准行
Author CMC documents
撰写 CMC 文档
AuroraPrime + Weave Bio only
仅 AuroraPrime + Weave Bio
AI-native
AI 原生
vs data / quality tooling
对比数据 / 质量工具
Sponsored talks tracked
追踪的赞助演讲
across all tracks
覆盖各 track
Product capability matrix — what each platform can author产品能力矩阵 — 各平台能撰写什么
Columns are concrete CMC document types. ● full · ◐ partial · · none. Directional positioning from public product info, not a feature-by-feature certification. The story is the emptiness: only AuroraPrime and Weave Bio author the filing — everyone else stops at data, modeling, or quality control.
列是具体的 CMC 文档类型。● 完整 · ◐ 部分 · · 无。基于公开产品信息的方向性定位，非逐项功能认证。重点在于这片空白：只有 AuroraPrime 与 Weave Bio 撰写递交文档——其余都止步于数据、建模或质量管控。
| Vendor | CMC Filing | Process & Method | Quality & Lifecycle | |||||
|---|---|---|---|---|---|---|---|---|
| M3 CMC | M2.3 QOS | IND/BLA | Proc Dev | Anal Method | Comparab. | Control | Stability | |
| AuroraPrime (AlphaLife Sciences)us | ● | ● | ● | ◐ | ◐ | ● | ◐ | ◐ |
| Weave Biorival | ◐ | ◐ | ● | · | · | ◐ | · | · |
| Genedata | · | · | · | ◐ | ◐ | ◐ | ◐ | · |
| Dassault Systèmes (BIOVIA) | · | · | · | ◐ | · | · | ◐ | · |
| Revvity Signals | · | · | · | ◐ | ◐ | · | · | · |
| Great Bay Bio | · | · | ◐ | ◐ | · | · | · | · |
| MasterControl | · | · | · | · | · | · | ◐ | · |
| Novasign | · | · | · | ◐ | · | · | · | · |
| Zifo | · | · | · | · | · | · | · | · |
AuroraPrime's white space at a manufacturing summitAuroraPrime 在制造类峰会上的白地带
The Bioprocessing Summit is rich in CMC science but almost empty of CMC *document authoring*. Across all sponsors, only AuroraPrime and Weave Bio actually generate regulatory/CMC documents — everyone else stops at data, modeling, or quality control. That gap between 'generating CMC data' and 'authoring the CMC filing' is exactly AuroraPrime's wedge.
The Bioprocessing Summit 的 CMC 科学很丰富，但 CMC「文档撰写」几乎空白。全体赞助商里，真正生成监管 / CMC 文档的只有 AuroraPrime 与 Weave Bio——其余都止步于数据、建模或质量管控。「生成 CMC 数据」与「撰写 CMC 递交文档」之间的这道缝，正是 AuroraPrime 的切入点。
Presentation coverage — what vendors discuss on stage台上讨论覆盖 — 厂商在演讲里谈到的文档类型
Derived from each sponsored talk's title + abstract: which CMC document types does the vendor actually talk about? Read side-by-side with the capability matrix above — stage narrative vs. real product. Equipment / instrument talks (no doc-type discussion) are omitted here.
从每场赞助演讲的标题 + 摘要提炼：厂商真正谈到哪些 CMC 文档类型？与上方能力矩阵并读——台上叙事 vs 真实产品。设备 / 仪器类演讲（不涉及文档类型）此处略去。
| Vendor (talks) | M3 CMC | M2.3 QOS | IND/BLA | Proc Dev | Anal Method | Comparab. | Control | Stability |
|---|---|---|---|---|---|---|---|---|
| Pfizer / Sanofi / USP (pharma panel) (1) | · | · | · | · | ● | · | ● | ● |
| Genedata (1) | · | · | · | ● | · | · | ● | · |
| Novartis (pharma session) (1) | · | · | · | · | · | ● | · | ● |
| Alexion–AstraZeneca Rare Disease (pharma session) (1) | · | · | · | · | ● | · | ● | · |
| US Pharmacopeia (pharma/standards session) (1) | · | · | · | · | ● | · | ● | · |
| MasterControl (1) | · | · | · | · | · | · | ● | · |
| Great Bay Bio (1) | · | · | ● | · | · | · | · | · |
| Denali Therapeutics (pharma session) (1) | · | · | ● | · | · | · | · | · |
AI capability overview — the broader digital pictureAI 能力概览 — 更广的数字化全景
Beyond document authoring, where does each vendor play across the summit's digital themes? Note the last column: regulatory doc authoring is checked for only two.
除文档撰写外，各厂商在峰会数字化主题上各踞何处？注意最后一列：监管文档撰写仅两家勾选。
| Vendor | Digital twin / modeling数字孪生 / 建模 | Predictive process control预测性工艺控制 | Advanced analytics / PAT先进分析 / PAT | CMC data platformCMC 数据平台 | QMS / compliance AIQMS / 合规 AI | Regulatory doc authoring监管文档撰写 |
|---|---|---|---|---|---|---|
| AuroraPrime | · | · | · | ✓ | · | ✓ |
| Weave Bio | · | · | · | · | · | ✓ |
| Genedata | · | · | ✓ | ✓ | · | · |
| MasterControl | · | · | · | · | ✓ | · |
| Dassault (BIOVIA) | ✓ | · | · | ✓ | · | · |
| Revvity Signals | · | · | ✓ | ✓ | · | · |
| Novasign | ✓ | ✓ | · | · | · | · |
| Yokogawa | · | ✓ | ✓ | · | · | · |
| Great Bay Bio | · | · | ✓ | · | · | · |
Sponsored & vendor presentations赞助与厂商演讲
Named vendor talks across the tracks (plus a few pharma CMC sessions for context). The digital/AI/document talks are where the competitive action is.
各 track 的具名厂商演讲（外加几场药企 CMC 场次作背景）。数字 / AI / 文档类演讲是竞争焦点所在。
Weave Bio
Digital Transformation & AI in Bioprocess生物工艺数字化转型与 AI
Sponsored Talk (Title to be Announced)
Sponsored talk by Weave Bio in the Digital Transformation & AI track — title and abstract to be announced (TBA). Weave Bio is an AI-native regulatory submission platform automating the full dossier lifecycle (authoring, review, publishing, HAQ response), including CMC submission content, and is AuroraPrime's most direct competitor present at the Summit.
Weave Bio 在「数字化转型与 AI」track 的赞助演讲——题目与摘要待定（TBA）。Weave Bio 是 AI 原生监管递交平台，自动化 dossier 全生命周期（撰写、审阅、发布、HAQ 答复），含 CMC 递交内容，是本会上 AuroraPrime 最直接的竞对。
Genedata
Analytical Intelligence分析智能
AI-native CMC: Transforming Data into Smarter Decisions
Advanced modalities, compressed timelines, and increasing regulatory expectations demand a new approach to CMC data. The talk shows how a unified digital CMC ecosystem with automated data product creation, analysis, and reporting enables AI-driven insights for deeper process understanding and more robust, evidence-based decisions from development through manufacturing.
先进模态、压缩的时间线与不断提升的监管预期，要求用全新方式处理 CMC 数据。演讲展示一个统一的数字 CMC 生态——自动化数据产品生成、分析与报告——如何带来 AI 驱动的洞察，支撑从开发到制造更稳健、有证据支撑的决策。
Jana Hersch, Head, Corporate Scientific Engagement
MasterControl
Intensified & Continuous Bioprocessing强化与连续生物工艺
Unlocking Manufacturing Intelligence: The AI Advantage in Regulated Environments
Bioprocessing manufacturers range from paper-based to digitally mature. Presents actionable strategies for implementing purpose-built, compliant AI that delivers measurable ROI — reducing quality review time by ~30% while keeping humans central to decisions. Discusses balancing innovation with compliance and maximizing AI business impact in manufacturing.
生物工艺制造商数字化程度参差不齐，从纸质到成熟数字化皆有。演讲给出可落地策略：部署专用、合规的 AI，带来可衡量的 ROI——质量审核时间约降 30%，同时让人始终处于决策核心。讨论如何在创新与合规之间取得平衡，并最大化 AI 在制造中的业务影响。
Jake Ure, Senior Product Manager
Zifo
Digital Transformation & AI in Bioprocess生物工艺数字化转型与 AI
Building a FAIR Data Foundation for Bioprocess Data
AI in bioprocessing depends on a strong data foundation. Instrument and manufacturing systems generate valuable data that often remain siloed. Zifo's FAIR Data Factory (FDF) transforms fragmented data into FAIR, semantically connected, AI-ready assets using configurable accelerators, ontologies, and data models. This foundation enables predictive process development, digital twins, technology transfer, manufacturing intelligence, and autonomous decision support.
生物工艺中的 AI 依赖坚实的数据底座。仪器与生产系统产生大量有价值数据，却常被孤岛化。Zifo 的 FAIR Data Factory（FDF）借助可配置加速器、本体与数据模型，把碎片化数据转化为 FAIR、语义互联、AI 就绪的资产。该底座支撑预测性工艺开发、数字孪生、技术转移、制造智能与自主决策支持。
Ragavi Shanmugam, Scientific Data Strategy Consultant, Bioinformatics
Great Bay Bio
Cell Line Development & Engineering细胞株开发与工程
LUNCHEON PRESENTATION: Progress of AI-Driven Site-Specific Integration Cell Line Development for IND Submission and Developability Assessment
Sponsored luncheon presentation: AlfaCell, an AI-driven, site-specific integration CLD platform, enables high expression titers of 4–16 g/L and research cell bank generation in ~1.5 months. Case studies demonstrate scalability, expression stability, and integration of AI-based developability assessment to support IND-enabling manufacturing readiness.
赞助午餐演讲：AlfaCell 是一个 AI 驱动的定点整合细胞株开发平台，表达滴度达 4–16 g/L，约 1.5 个月即可生成研究细胞库。案例展示其可扩展性、表达稳定性，以及把 AI 可开发性评估整合进来，支撑 IND 申报制造就绪。
Michael Chen, Co-Founder & CEO
Thermo Fisher Scientific
Cell Line Development & Engineering细胞株开发与工程
Stable High-Producing Clones in 14 Weeks: Accelerated Cell Line Development (CLD) with the Gibco CHOvantage GS CLD Kit
Sponsored vendor talk: CLD remains a major bottleneck due to long timelines, variable productivity, and limited pool-to-clone predictability, particularly for complex biologics such as bispecific antibodies and Fc-fusion proteins. A novel transposon-based CHO-K1 CLD platform generated stable, high-producing cell lines in under 14 weeks, with 3–5 g/L pools correlating to clone titers >7 g/L, scaling up while maintaining stable expression and product quality.
赞助厂商演讲：细胞株开发仍是主要瓶颈——周期长、产能波动、pool 到克隆的可预测性有限，对双特异抗体、Fc 融合蛋白等复杂生物药尤甚。一种新型转座子 CHO-K1 平台可在 14 周内生成稳定高产细胞株，3–5 g/L 的 pool 对应克隆滴度 >7 g/L，放大时仍保持表达稳定与产品质量。
Michalis Mastri, Manager, R&D / Staff Scientist
Thermo Fisher Scientific
Analytical Intelligence分析智能
When Residual DNA Data Drives Development Decisions: The Importance of Quantitative Confidence
Residual host cell DNA quantitation is increasingly performed throughout process development to evaluate purification strategies, assess impurity clearance, and support process understanding not just for regulatory compliance. However, development-stage/in-process samples often contain complex matrices, such as high protein and high salt backgrounds, that can affect DNA recovery and quantitative performance. This presentation examines how process-relevant matrices influence residual DNA quantitation across multiple workflow approaches. We will explore factors that impact quantitative confidence and discuss the importance of generating reliable residual DNA measurements that can support decision making throughout bioprocess development, characterization, and in-process and lot-release testing.
残留宿主细胞 DNA 定量在工艺开发全程被越来越多地用于评估纯化策略、判断杂质清除、支撑工艺理解，而不只是满足监管合规。但开发阶段 / 在制样品常含复杂基质（高蛋白、高盐背景），会影响 DNA 回收与定量表现。本演讲考察工艺相关基质如何在多种工作流下影响残留 DNA 定量，探讨影响定量可信度的因素，并强调生成可靠的残留 DNA 数据、支撑生物工艺开发、表征、在制与放行检测决策的重要性。
Shriya Sahu, Product Manager
Cytiva
Intensified & Continuous Bioprocessing强化与连续生物工艺
LUNCHEON PRESENTATION: Intensifying Product Concentration and Buffer Exchange via SPTFF and Dialysis
As biologics manufacturing moves toward continuous processing, enhanced understanding and novel approaches in UF/DF are required. This talk covers recent evolutions in single-pass TFF (SPTFF), such as strategies that ameliorate issues in flushing, loading, and recovery caused by TMP nonuniformity over filter length. Orthogonal technologies to continuous UF/DF will also be discussed, including the potential use of countercurrent dialysis as a diafiltration method with high buffer-use efficiency.
随着生物药生产迈向连续工艺，UF/DF 需要更深入的理解与全新方法。演讲介绍单程切向流过滤（SPTFF）的最新演进，例如缓解因滤器沿程 TMP 不均导致的冲洗、载样与回收问题的策略；并讨论连续 UF/DF 的正交技术，包括将逆流透析作为高缓冲液利用率的透滤方法。
Matthew Becker, Senior Scientist, Filtration
Catalent Pharma Solutions
Cell Line Development & Engineering细胞株开发与工程
LUNCHEON PRESENTATION: A Simple and Tunable Expression Platform for Rapid Transient-to-Stable Pool Production of Complex Biologics
Sponsored luncheon presentation: Catalent's GPEx Lightning platform enables tunable gene expression to accelerate transient-to-stable pool development for complex biologics. Combining high-copy genomic integration with plasmid ratioing, it delivers precise control of multi-gene expression, improving titers and product quality and supporting rapid progression from candidate selection to gene-to-GMP.
赞助午餐演讲：Catalent 的 GPEx Lightning 平台通过可调基因表达，加速复杂生物药从瞬转到稳定 pool 的开发。结合高拷贝基因组整合与质粒配比，精确控制多基因表达，提升滴度与产品质量，支撑从候选筛选到 gene-to-GMP 的快速推进。
Chad Hall, Principal Scientist, R&D Mammalian Cell Biology
Roche CustomBiotech
Cell Line Development & Engineering细胞株开发与工程
Precision in Process: Advanced Assays and Workflows Using Cedex Bioanalyzers
Sponsored vendor presentation (Roche CustomBiotech) on advanced assays and workflows using Cedex Bioanalyzers for bioprocess analytics.
Roche CustomBiotech 赞助演讲：介绍基于 Cedex Bioanalyzer 的先进分析方法与工作流，用于生物工艺分析。
Ryan Lybarger
Thomson Instrument Company
SYMPOSIUM: Novel & Alternative Expression Systems专题研讨：新型与替代表达系统
LUNCHEON PRESENTATION: Tips and Tricks in Speeding Up Transient HEK293 and Transient/Stable CHO from 96-Well, 24-Well, and 6-Well 125mL–7L Optimum Growth Flasks
Vendor luncheon presentation: conditions for plasmids, transient HEK293, and transient/stable CHO from 96-well, 24-well, and 6-well 125mL–7L Optimum Growth flasks must be maintained at small scale. Data is presented on techniques and technology to get high amounts of protein in smaller volumes with fast techniques — proven technologies for protein production and structural biology.
厂商午餐演讲：在小规模下维持质粒、瞬转 HEK293、瞬转/稳定 CHO 的培养条件（96 孔、24 孔、6 孔 125mL–7L Optimum Growth 摇瓶）。展示在更小体积下用快速技术获得高蛋白产量的方法与技术——已验证的蛋白生产与结构生物学方案。
Sam Ellis, CEO
RedShift Bio
Cell Culture & Upstream Processing细胞培养与上游工艺
Why Bioprocess Teams Are Switching to Halcon for At-Line, In-Line Titer
Sponsored talk demonstrating how the HaLCon platform delivers precise, real-time at-line and in-line titer quantification at the point of manufacture — high-fidelity, liquid-chromatography-grade analysis within the upstream workflow, eliminating reliance on lagging core-laboratory HPLC assays and replacing redundant, low-accuracy screening devices. Shows how upstream teams can make immediate data-driven feeding and harvest decisions while reducing sample-processing bottlenecks.
赞助演讲：展示 HaLCon 平台如何在制造现场提供精确、实时的 at-line / in-line 滴度定量——在上游工作流内提供媲美液相色谱的高保真分析，摆脱滞后的中心实验室 HPLC 检测，替换冗余、低精度的筛查设备。让上游团队据数据即时决定补料与收获，同时缓解样品处理瓶颈。
Sebastian Arevalo, CCO
Sunresin
Formulation, Stability & Delivery of Biologics生物药制剂、稳定性与递送
LUNCHEON PRESENTATION: Streamlined Sequential Chromatography for the Purification of Recombinant Nanobody-Fc Fusion Protein
Sponsored luncheon presentation highlighting chromatography purification advances using engineered recombinant Protein A with enhanced alkaline stability and binding capacity. The rProteinA affinity resin was used with ion-exchange and hydrophobic chromatography resins in sequential purification of a nanobody-Fc fusion molecule to achieve over 95% purity, emphasizing resin selection in overcoming biomolecule purification complexity.
赞助午餐演讲：介绍基于工程化重组 Protein A（碱稳定性与结合能力增强）的色谱纯化进展。rProteinA 亲和树脂与离子交换、疏水色谱树脂结合，对纳米抗体-Fc 融合分子进行序贯纯化，纯度超 95%，强调树脂选择在攻克生物分子纯化复杂性中的作用。
Simona Serban, Global Director, Life Science Applications
Teknova
Formulation, Stability & Delivery of Biologics生物药制剂、稳定性与递送
The Rise of Modular Manufacturing: Scalable Solutions to Accelerate Novel Therapy Development
Sponsored vendor presentation: novel therapeutic development is increasingly individualized, requiring smaller customized batches of reagents and buffers across the clinical pipeline. Existing bioprocessing infrastructure was not designed for next-generation therapies. Teknova's modular manufacturing platform helps developers across cell and gene therapy, mRNA, and next-generation antibodies (ADCs and multispecifics) accelerate into the clinic, with guidance on criteria for evaluating reagent sourcing.
赞助厂商演讲：新型疗法开发越来越个性化，需要在临床管线各环节提供更小批量的定制试剂与缓冲液。现有生物工艺基础设施并非为下一代疗法设计。Teknova 的模块化制造平台帮助细胞与基因治疗、mRNA、下一代抗体（ADC 与多特异）开发者加速进入临床，并就如何评估试剂来源给出标准。
Bella Neufeld, Vice President, Operations, New Product Development
Ecolab Life Sciences
Formulation, Stability & Delivery of Biologics生物药制剂、稳定性与递送
Impurity Control in Complex Monoclonal Antibody Purification via Next-Generation Resins
Sponsored vendor presentation: a new wave of monoclonal antibody therapeutics uses complex molecular structures for enhanced efficacy, requiring new synthetic pathways with unique purification challenges. The choice of affinity resin is increasingly critical to obtaining scalable, commercially viable results. Describes how unique features of modern affinity resins create robust purification workflows for even the most challenging molecules.
赞助厂商演讲：新一波单抗疗法采用复杂分子结构以增强疗效，带来全新合成路径与独特纯化挑战。亲和树脂的选择对获得可放大、商业可行的结果愈发关键。介绍现代亲和树脂的独特特性如何为最具挑战的分子构建稳健纯化工作流。
Aaron Moulin, Global Technical Consultant, Bioprocessing Field Applications
Tosoh Bioscience
Intensified & Continuous Bioprocessing强化与连续生物工艺
Advanced Characterization of Protein A Chromatography for High-Purity 2-Step Purification Processes
Sponsored vendor talk: advanced characterization of a next-generation Protein A resin, emphasizing wash-step optimization for host cell protein (HCP) reduction and extended cycling performance. Improved impurity removal during Protein A capture reduces burden on downstream steps and supports robust two-step chromatography. Demonstrates a two-step workflow combining Protein A capture with a salt-tolerant cation-exchange (CEX) resin, plus an integrated continuous version.
赞助厂商演讲：对下一代 Protein A 树脂进行先进表征，重点是洗涤步骤优化以降低宿主细胞蛋白（HCP）并延长循环寿命。Protein A 捕获阶段更好的杂质去除减轻了下游负担，支撑稳健的两步色谱。展示 Protein A 捕获 + 耐盐阳离子交换（CEX）树脂的两步工作流，以及集成的连续版本。
Jennifer Knister, Product Manager, Process Solutions — Multi-Column Chromatography, Process Media
Yokogawa Electric
Digital Transformation & AI in Bioprocess生物工艺数字化转型与 AI
Predictive Control & Automation for Multi-Bioreactor Cultivation
Our new bioprocess system enables predictive control and automation for multi-bioreactor cultivation, supporting parallel monitoring and control of multiple culture units. It automatically collects and integrates data from bioreactors, sensors, and offline analytical instruments, applies predictive models to each bioreactor, and drives model-based workflows to deliver consistent, scalable, and efficient cultivation operations.
全新的生物工艺系统实现多生物反应器培养的预测控制与自动化，支持对多个培养单元的并行监控。系统自动采集并整合来自反应器、传感器与离线分析仪器的数据，对每个反应器施加预测模型，驱动基于模型的工作流，以实现一致、可放大、高效的培养操作。
Hiroaki Yamanaka, Bioprocess Application Scientist, Biology Business Development
Novasign
Digital Transformation & AI in Bioprocess生物工艺数字化转型与 AI
Digital Twins in Bioprocessing: Industrial Showcases for Biosimilar Development, Viral Vectors, Media Optimization, UF/DF, and End-to-End Process Control
This presentation explores how digital twins, combining mechanistic process understanding, AI, and process data, enable smarter, faster bioprocess development and control. Six industrial use cases demonstrate the value of digital twins: accelerated biosimilar development using PAT and glycan modeling; reduced experimental effort in viral vector process design; media optimization through time-resolved nutrient uptake prediction; UF/DF development guided by digital membrane and recovery modeling; scale-up informed by CFD-based reactor behavior; and fully integrated digital control of continuous bioprocesses sustained for over 30 days.
演讲探讨数字孪生如何结合机理工艺理解、AI 与工艺数据，实现更智能、更快速的生物工艺开发与控制。六个工业用例展示其价值：用 PAT 与糖基化建模加速生物类似药开发；降低病毒载体工艺设计的实验量；通过时间分辨的营养摄取预测优化培养基；用数字膜与回收建模指导 UF/DF 开发；用基于 CFD 的反应器行为指导放大；以及对连续生物工艺持续 30 天以上的全集成数字控制。
Mark Duerkop, CEO
Revvity Signals
Digital Transformation & AI in Bioprocess生物工艺数字化转型与 AI
LUNCHEON PRESENTATION: From Tasks to Process Execution: Orchestrating Scientific Work beyond the Instrument
Scientific work is still coordinated manually across experiments, teams, and systems. Signals LabGistics introduces a process-centric execution layer that orchestrates workflows beyond individual lab steps. By connecting experiments, configurable process logic, and explicit decision points, Signals LabGistics enables consistent execution across diverse scientific workflows. This session demonstrates bioprocess workflows in action, showing how teams move from fragmented coordination to structured execution—creating the foundation for scalable automation and AI-driven optimization.
科研工作至今仍在实验、团队与系统之间靠人工协调。Signals LabGistics 引入以流程为核心的执行层，把工作流编排到单个实验步骤之上。通过连接实验、可配置的流程逻辑与明确的决策节点，实现跨多样科研工作流的一致执行。演讲现场演示生物工艺工作流，展示团队如何从碎片化协调走向结构化执行——为可放大的自动化与 AI 驱动优化打底。
Michael Barnes, Product Manager, Process & Workflows Solutions
Novartis (pharma session)
Gene Therapy CMC & Analytics基因治疗 CMC 与分析
KEYNOTE: CMC for in vivo CAR T Manufacturing — Opportunities, Challenges, and the Road Ahead
In vivo CAR T manufacturing represents a potential paradigm shift by eliminating patient-specific ex vivo manufacturing and enabling scalable, off-the-shelf therapies. Success will be largely determined by CMC readiness; the talk evaluates in vivo CAR T through a CMC lens focusing on consistency, scalability, formulation stability, analytical control, and comparability.
体内 CAR T 制造可能带来范式转变——免去针对患者的体外制造，实现可放大、现货型疗法。成败很大程度取决于 CMC 就绪度；演讲从 CMC 视角评估体内 CAR T，聚焦一致性、可放大性、制剂稳定性、分析控制与可比性。
Nripen Singh, Executive Director and Site Head, Process Development, TRD CGT
Alexion–AstraZeneca Rare Disease (pharma session)
Gene Therapy CMC & Analytics基因治疗 CMC 与分析
CMC and Analytical Strategy — Case Study from Alexion
Novel capsids modify wildtype AAV serotypes (via inserts) to improve efficacy and tissue specificity, but complex capsids require advanced analytics to characterize and assess lot-to-lot variability. Several analytical methods focusing on abundance, polydispersity, and function of the insert are used to elucidate attributes impacting final product quality.
新型衣壳通过插入序列改造野生型 AAV 血清型，以提升疗效与组织特异性，但复杂衣壳需要先进分析来表征并评估批间变异。多种分析方法围绕插入序列的丰度、多分散性与功能，阐明影响最终产品质量的关键属性。
William Lee, Research Associate, AAV Analytical Method Development
Denali Therapeutics (pharma session)
SYMPOSIUM: CMC for ADC & Next-Generation Conjugates专题研讨：ADC 与下一代偶联物的 CMC
Regulatory CMC Considerations for Antibody-Drug Conjugates
Talk on regulatory CMC considerations for antibody-drug conjugates. (No detailed abstract was published on the agenda page.)
关于抗体药物偶联物（ADC）监管 CMC 考量的演讲。（议程页未发布详细摘要。）
Charles Morgan, Executive Director, Regulatory CMC
US Pharmacopeia (pharma/standards session)
Oligonucleotide and Peptide CMC and Manufacturing寡核苷酸与多肽 CMC 及制造
Quality Frameworks for Oligonucleotides and Peptides: USP Standards Supporting CMC and Manufacturing
Outlines quality frameworks for therapeutic oligonucleotides and peptides, emphasizing how public standards strengthen CMC development and manufacturing. Discusses challenges in impurity control, starting-material characterization, and analytical consistency across product lifecycles, with updates on new and upcoming USP documentary and physical reference standards.
勾勒治疗性寡核苷酸与多肽的质量框架，强调公共标准如何强化 CMC 开发与制造。讨论杂质控制、起始物料表征、贯穿产品生命周期的分析一致性等挑战，并更新 USP 新出与即将发布的文献及实物参考标准。
Diane McCarthy, Vice President, Global Biologics
Pfizer / Sanofi / USP (pharma panel)
SYMPOSIUM: RNA and LNP Production and Formulation专题研讨：RNA 与 LNP 生产及制剂
PANEL DISCUSSION: CMC and Quality of RNA-Based Medicines
Panel covering identification and control of RNA-related impurities (dsRNA, truncated transcripts, residual enzymes) that can impact potency and immunogenicity; robust analytical methods for RNA integrity, sequence fidelity, and degradation through manufacturing and storage; and defining critical quality attributes for RNA and LNP formulations to ensure consistent potency.
圆桌讨论：识别并控制 RNA 相关杂质（dsRNA、截短转录本、残留酶）对效价与免疫原性的影响；建立稳健分析方法以衡量制造与储存全程的 RNA 完整性、序列保真度与降解；为 RNA 与 LNP 制剂界定关键质量属性（CQA）以确保效价一致。
Lawrence C. Thompson, Associate Research Fellow, Analytical R&D (moderator); Wei-Chiang Chen; Sarita Kattel; Khaled Yamout
Company profiles — digital / AI / CMC software vendors公司概况 — 数字 / AI / CMC 软件厂商
Company-level deep dive for the competitively-relevant cluster. AuroraPrime is the benchmark row; Weave Bio is the direct competitor.
对相关集群的公司层面深挖。AuroraPrime 为基准行，Weave Bio 为直接竞对。
AuroraPrime (AlphaLife Sciences)
AI-nativeAI 原生BPS 2026UsChina (alphalifesci.com)中国（alphalifesci.com） · 2023 · Private未上市 · Not disclosed · Mid-size startup中等规模初创
AI-native platform authoring eCTD-ready regulatory documents — including CMC Module 3, QOS, and IND/BLA CMC sections — from underlying development data.
AI 原生平台：从开发数据直接生成 eCTD 就绪监管文档——含 CMC 模块 3、质量综述（QOS）与 IND/BLA CMC 章节。
AI: End-to-end AI document generation with cross-document propagation and full audit trail — the only true CMC-authoring peer at this manufacturing-focused summit.端到端 AI 文档生成，支持跨文档语义传播与完整审计轨迹——在这个以制造为主的峰会上，唯一真正做 CMC 撰写的同类。
Strengths优势
- True CMC document authoring (M3 / M2.3 / IND-BLA), not just data tooling
- AI-native architecture with cross-document propagation
- Multi-region regulatory fluency (FDA / EMA / PMDA / NMPA)
- Exhibiting at The Bioprocessing Summit 2026 (Corporate Support Sponsor)
- 真正的 CMC 文档撰写（M3 / M2.3 / IND-BLA），而非仅数据工具
- AI 原生架构，支持跨文档语义传播
- 多区域监管能力（FDA / EMA / PMDA / NMPA）
- 已参展 The Bioprocessing Summit 2026（Corporate Support 赞助商）
Weaknesses弱点
—
Recent: 近况：Exhibiting at The Bioprocessing Summit 2026 (Aug 10–13, Boston) — first appearance in the bioprocessing/CMC arena.参展 The Bioprocessing Summit 2026（8/10–13，波士顿）——首次进入生物工艺 / CMC 场景。 alphalifesci.com ↗
Weave Bio
AI-nativeAI 原生BPS 2026Direct competitorSan Francisco, CA美国旧金山，CA · 2022 · Series AA 轮 · $36M total ($20M Series A) · 30–60 est.约 30–60 人
AI-native, 'expert-led' regulatory platform (CEO Brandon Rice) automating the full dossier lifecycle from preclinical to post-market — data organization → authoring → review → publishing → HAQ response — using eCTD-formatted templates, including CMC submission content.
AI 原生「专家主导（expert-led）」监管平台（CEO Brandon Rice）：覆盖临床前到上市后的 dossier 全生命周期——数据整理 → 撰写 → 审阅 → 发布 → HAQ 答复——采用 eCTD 模板，含 CMC 递交内容。
AI: Direct competitor to AuroraPrime — the only other AI reg-document author present; claims >50% faster regulatory timelines with a human-in-the-loop model; sponsored talk in the Digital Transformation & AI track.AuroraPrime 的直接竞对——本会唯一另一家做 AI 监管文档撰写的；主张监管周期提速 >50%，采用 human-in-the-loop 模式；在 Digital Transformation & AI track 有赞助演讲。
Strengths优势
- Best-funded AI-native regulatory startup ($36M total; $20M Series A led by USVP, Oct 2025)
- Full submission lifecycle (preclinical → IND → BLA → post-market → HAQ)
- Strong named-customer roster: Recursion, argenx, Shattuck Labs, VistaGen, Trace Biosciences; Parexel & Syner-G channel
- Claims >50% faster regulatory timelines; global expansion (EU / Japan / LatAm) underway
- Sponsoring + presenting at The Bioprocessing Summit 2026
- AI 原生监管初创中融资最高（累计 $36M；2025/10 完成 USVP 领投的 $20M A 轮）
- 覆盖递交全生命周期（临床前 → IND → BLA → 上市后 → HAQ）
- 具名客户阵容强：Recursion、argenx、Shattuck Labs、VistaGen、Trace Biosciences；Parexel 与 Syner-G 渠道
- 主张监管周期提速 >50%；正在全球扩张（欧盟 / 日本 / 拉美）
- 赞助并在 The Bioprocessing Summit 2026 演讲
Weaknesses弱点
- Starts at dossier — no upstream process/study design
- Submission-shell focus; CMC depth (M3 narrative) unproven
- 起点在 dossier——不覆盖上游工艺 / 研究设计
- 聚焦递交外壳；CMC 深度（M3 叙述）尚未验证
Recent: 近况：Sponsored talk in 'Digital Transformation & AI in Bioprocess' (Aug 13). Raised $20M Series A (led by USVP; Innovation Endeavors, Magnetic Ventures, Character, TMV, Serrado) in Oct 2025, bringing total to $36M; won 'Biotech AI Innovation of the Year' for preclinical IND prep; expanding to EU / Japan / LatAm.在「Digital Transformation & AI in Bioprocess」做赞助演讲（8/13）。2025/10 完成 $20M A 轮（USVP 领投，Innovation Endeavors／Magnetic Ventures／Character／TMV／Serrado 跟投），累计融资达 $36M；凭临床前 IND 准备获「Biotech AI Innovation of the Year」；正扩张至欧盟 / 日本 / 拉美。 weave.bio ↗
Genedata
CMC / digital softwareCMC / 数字软件BPS 2026Basel, Switzerland瑞士巴塞尔 · 1997 · Private (Danaher)未上市（Danaher 旗下） · Acquired by Danaher (2024) · 300+300+ 人
Unified digital CMC ecosystem: automated data product creation, analysis, and reporting from development through manufacturing.
统一的数字 CMC 生态：从开发到制造的自动化数据产品生成、分析与报告。
AI: 'AI-native CMC' — turns process/analytical data into AI-driven insights and reports, but does not author the regulatory narrative.「AI-native CMC」——把工艺 / 分析数据转成 AI 驱动洞察与报告，但不撰写监管叙述文本。
Strengths优势
- Deep CMC data backbone across modalities
- Strong analytical + process data automation
- Talk: 'AI-native CMC: Transforming Data into Smarter Decisions'
- 跨模态的深厚 CMC 数据底座
- 分析 + 工艺数据自动化能力强
- 演讲：「AI-native CMC：把数据变成更聪明的决策」
Weaknesses弱点
- Data/reporting platform — not a regulatory document author
- Heavy enterprise deployment
- 数据 / 报告平台——不做监管文档撰写
- 企业级部署偏重
Recent: 近况：Presenting 'AI-native CMC' in the Analytical Intelligence track (Aug 11–12).在 Analytical Intelligence track 演讲「AI-native CMC」（8/11–12）。 genedata.com ↗
MasterControl
CMC / digital softwareCMC / 数字软件BPS 2026Salt Lake City, UT美国盐湖城，UT · 1993 · Private未上市 · PE-backed · 1,000+1,000+ 人
Quality and manufacturing execution software for regulated environments — document control, records, and AI-assisted quality review.
面向受监管环境的质量与制造执行软件——文档管控、记录与 AI 辅助质量审核。
AI: AI for quality review (~30% review-time reduction) inside a QMS — document *control*, not document *authoring*.QMS 内的 AI 质量审核（审核时间约降 30%）——做文档「管控」，非文档「撰写」。
Strengths优势
- Entrenched QMS/MES in GxP manufacturing
- Talk: 'Unlocking Manufacturing Intelligence: The AI Advantage in Regulated Environments'
- 在 GxP 制造中根基深厚的 QMS/MES
- 演讲：「解锁制造智能：受监管环境下的 AI 优势」
Weaknesses弱点
- Document control / workflow — not authoring
- No CMC narrative generation
- 文档管控 / 流程——非撰写
- 不生成 CMC 叙述文本
Recent: 近况：Sponsored talk in the Continuous Processing track (Aug 12–13).在 Continuous Processing track 做赞助演讲（8/12–13）。 mastercontrol.com ↗
Dassault Systèmes (BIOVIA)
CMC / digital softwareCMC / 数字软件BPS 2026Vélizy-Villacoublay, France法国维利耶－维拉库布莱 · 1981 (Dassault) · Public (Euronext: DSY)上市（Euronext: DSY） · Public · 20,000+20,000+ 人
Scientific informatics and process modeling for bioprocess development and quality management.
面向生物工艺开发与质量管理的科学信息学与工艺建模平台。
AI: Modeling, ELN/LIMS and quality data — supports process understanding, not regulatory authoring.建模、ELN/LIMS 与质量数据——支撑工艺理解，不做监管撰写。
Strengths优势
- Broad scientific-informatics suite
- Public-company scale
- 科学信息学套件完整
- 上市公司规模
Weaknesses弱点
- Not a document author
- Heavy platform
- 不做文档撰写
- 平台偏重
Recent: 近况：Corporate sponsor at The Bioprocessing Summit 2026.The Bioprocessing Summit 2026 企业赞助商。 3ds.com/products/biovia ↗
Revvity Signals
CMC / digital softwareCMC / 数字软件BPS 2026Waltham, MA美国沃尔瑟姆，MA · 2023 (spun from PerkinElmer) · Public (NYSE: RVTY)上市（NYSE: RVTY） · Public · Part of RevvityRevvity 旗下
R&D informatics and analytics for biologics characterization and method data.
面向生物药表征与方法数据的研发信息学与分析平台。
AI: Analytical data management & analytics — not document authoring.分析数据管理与分析——非文档撰写。
Strengths优势
- Strong analytical informatics
- Public-company backing
- 分析信息学能力强
- 上市公司背书
Weaknesses弱点
- Data tool, not author
- 数据工具，非撰写
Recent: 近况：Corporate sponsor at The Bioprocessing Summit 2026.The Bioprocessing Summit 2026 企业赞助商。 revvitysignals.com ↗
Zifo
CMC / digital softwareCMC / 数字软件BPS 2026Chennai, India / Global印度金奈 / 全球 · 2012 · Private未上市 · Private · 1,000+1,000+ 人
Scientific data management and R&D IT services for life-sciences digitalization.
面向生命科学数字化的科学数据管理与研发 IT 服务。
AI: Data integration & digitalization services — not authoring.数据集成与数字化服务——非撰写。
Strengths优势
- Broad scientific data-management services
- 科学数据管理服务面广
Weaknesses弱点
- Services/IT — no document product
- 服务 / IT——无文档产品
Recent: 近况：Speaking slot (TBA) in the Digital Transformation & AI track (Aug 12–13).在 Digital Transformation & AI track 有演讲位（待定，8/12–13）。 zifornd.com ↗
Great Bay Bio
AI-nativeAI 原生BPS 2026Hong Kong / China中国香港 / 中国大陆 · 2018 · Private未上市 · VC-backed · Not disclosed未披露
AI-driven site-specific integration cell line development with AI-based developability assessment to support IND-enabling manufacturing.
AI 驱动的定点整合细胞株开发，结合 AI 可开发性评估，支撑 IND 申报制造就绪。
AI: AI for CLD + IND-readiness packaging — touches the IND CMC dossier edge, but not full document authoring.AI 做细胞株开发 + IND 就绪打包——触及 IND CMC dossier 边缘，但非完整文档撰写。
Strengths优势
- AI-native CLD with strong titers (4–16 g/L)
- Talk: 'AI-Driven SSI Cell Line Development for IND Submission'
- AI 原生细胞株开发，滴度强（4–16 g/L）
- 演讲：「AI 驱动的定点整合细胞株开发，面向 IND 申报」
Weaknesses弱点
- Upstream CLD focus; not a CMC document author
- 聚焦上游细胞株开发；非 CMC 文档撰写
Recent: 近况：Luncheon talk in Cell Line Development & Engineering track (Aug 11–12).在 Cell Line Development & Engineering track 做午餐演讲（8/11–12）。 greatbaybio.com ↗
Novasign
AI-nativeAI 原生BPS 2026Vienna, Austria奥地利维也纳 · 2019 · Private未上市 · Private · <50<50 人
Hybrid-modeling digital twins combining mechanistic understanding, AI, and process data for bioprocess development and control.
混合建模数字孪生：结合机理理解、AI 与工艺数据，用于生物工艺开发与控制。
AI: Digital twins for process characterization — informs CMC process-development data, not the filing text.用于工艺表征的数字孪生——为 CMC 工艺开发数据提供支撑，不生成递交文本。
Strengths优势
- Digital-twin depth across upstream/downstream
- 上下游数字孪生能力深
Weaknesses弱点
- Modeling tool — not a document author
- 建模工具——非文档撰写
Recent: 近况：Digital-twins talks in the Digital Transformation & AI track (Aug 12–13).在 Digital Transformation & AI track 做数字孪生演讲（8/12–13）。 novasign.at ↗
Coverage reflects publicly marketed capabilities; treat as directional positioning, not a feature-by-feature certification. Sponsor list + talks researched from bioprocessingsummit.com (2026-06).覆盖度反映公开宣传的能力，请视为方向性定位而非逐项功能认证。赞助商名单与演讲来自 bioprocessingsummit.com（2026-06）整理。